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Adjusted Life Years (QALYs) was 1.48 and 1.42 respectively, or
$1.02 mill. per additional QALY (all values discounted at 3%).
This amount would be $199,000 if patients used apomorphine
as conventional therapy, $124.00 if EQ-5D were used to measure
HRQOL, $99,000 if indirect costs were included. If Duodopa
improves disease severity by one H&Y stage, the therapy will 
be cost-saving. CONCLUSIONS: The cost-effectiveness of
Duodopa depends in particular on the cost of alternative thera-
pies (i.e. apomorphine and oral drugs) and the extent to which
Duodopa postpones PD progression. Also, the method for cap-
turing quality-of-life has a considerable impact on the cost-effec-
tiveness ratio. The study indicates that variability in utility scores
may be much greater than previously anticipated.
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OBJECTIVE: To estimate for use in economic modeling, the
time-dependent effects of deep brain stimulation (DBS) in
patients with Parkinson’s Disease (PD) using meta-analysis of
case series. METHODS: A discrete event simulation of the
course of advanced PD was created. It requires time-dependent
functions of the effects of DBS. To obtain these, we searched the
PUBMED, OVID and the Science Citation Index databases
between 1980 and 2004 for papers reporting longitudinal expe-
rience with DBS. Data were extracted by three expert reviewers.
The effect of DBS was measured at various time-points relative
to baseline, while on and off medication. Time-dependent
growth curves were developed by ﬁtting the estimates as func-
tions of time under ﬁxed and random-effects models. RESULTS:
Comparisons to baseline in the 85 studies retained showed that
while off medication, activating the stimulator improved ADL
rapidly (by 50.0% at 3 months) but then improvement declined
slowly following a quadratic polynomial. The effect was much
weaker and decline linearly while on medication but levodopa
dose declined steadily, from a reduction of 590.52 (439.9–741.2)
mg at 3 months to 633.8 (497.4–770.2) mg after 1 year. Motor
skills improved by 47.2% and then more slowly following a frac-
tional polynomial curve. CONCLUSION: These growth curves
will be used to estimate the course of individual patients in sim-
ulation providing much more accurate reﬂection of the actual
effects than traditional point estimates or transition probabili-
ties. Given that studies can be either too small or too limited in
scope to provide sound estimates of the effect of treatment, the
results of meta-analytic curve ﬁtting can be used as precise inputs
to build an economic model.
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OBJECTIVES: To measure the average health care cost per
patient with relapsing remitting multiple sclerosis (RRMS) by
level of severity in Portugal. Additionally, and in contrast to pre-
vious studies, the health care cost of a relapse by severity level
is also calculated. METHODS: The study adopts the perspective
of the National Health Service (NHS) and carries out a cost of
treatment analysis. Information on treatment proﬁles and
resource use was gathered through a modiﬁed Delphi Panel
involving eight specialist physicians from different hospitals
throughout the country. Each completed a questionnaire based
on four clinical cases representing categories of the Expanded
Disability Severity Scale (EDSS). Information was collected on
the use of inpatient care, pharmaceuticals, ambulatory visits, and
various other resources. These were valued using national infor-
mation on unit costs from a variety of sources. RESULTS: Total
health care costs per patient, in 2003, were estimated to range
from €11,515 (EDSS £ 3) to €22,876 (EDSS ≥ 6.5). At each level
of severity the cost of treatment rises with the most signiﬁcant
increase occurring between EDSS £ 3 and 3.5 £ EDSS ≥ 4.5. The
highest expenditures are associated with the use of interferons
(between 44% and 82% of the total costs). When patients have
a relapse, health care costs vary between €3412 (EDSS £ 3) and
€6718 (EDSS ≥ 6.5). At intermediate EDSS levels the costs of a
relapse are €4422 for 3.5 £ EDSS ≥ 4.5 and €6495 for 5 £ EDSS
≥ 6. The most signiﬁcant cost component for relapses is that
related to inpatient stays. CONCLUSIONS: Though the number
of persons with MS in Portugal is small (estimates suggest
around 5000 patients), the costs to the health system are very
large. Therapeutic strategies that reduce the impact of the disease
(e.g. relapse avoidance) can bring about signiﬁcant cost-savings.
The results may be used as input to cost-effectiveness analyses
and more widely in health care planning and policy.
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OBJECTIVES: During the last decade, the introduction of new
disease-modifying drugs (DMDs) for MS gave rise to a number
of studies on the economic burden of the disease and the cost-
effectiveness of different treatment options. Since these surveys
were conducted before DMDs were established as part of stan-
dard treatment regimens, there is a need for up-to-date cost-of-
illness studies that can be used for the economic evaluation of
new treatments. Therefore, European Health Economics has
conducted a European-wide, cross-sectional bottom-up survey
on the costs of MS, involving at least nine countries.
METHODS: The study used a standardised mailed questionnaire
providing data on demographics, direct medical and non-medical
costs, informal care needs, productivity losses, relapses, utility
and fatigue. RESULTS: The results were analysed by country,
both for the whole sample and by level of disease severity mea-
sured with the Expanded Disability Status Scale (EDSS). Patients
were recruited by MS clinics and MS societies, and the response
rate ranged between 35% and 72%. Overall, the study includes
over 10,000 patients. The samples per country are thus sufﬁ-
ciently large to analyse the change in costs and utility for all
levels of disease severity. For example, in Sweden, the total
annual cost per MS patient was estimated at €53,580, with costs
increasing sevenfold for patients with severe disease compared
to patients with no or very mild disability, from €16,338 to
€116,502. DMDs were used by 43% of patients and accounted
for 11% of total costs. In addition, analysis of variations across
countries illustrates the impact of different health care and eco-
nomic systems on patient management, total costs and distribu-
tion of resources. For example, services represented 29% of total
costs in Sweden, due to a unique extensive home service avail-
able to severe patients. CONCLUSIONS: This alternative to
institutionalisation reduces nursing home costs and informal care
needs.
